Emily Bodnar
Stock Analyst at HC Wainwright & Co.
(0.77)
# 3,857
Out of 4,886 analysts
312
Total ratings
22.26%
Success rate
-29.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Bodnar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JSPR Jasper Therapeutics | Maintains: Buy | $40 → $20 | $3.02 | +562.25% | 10 | Jul 7, 2025 | |
| NXTC NextCure | Reiterates: Buy | $3 | $0.46 | +556.31% | 9 | Jul 1, 2025 | |
| FEMY Femasys | Reiterates: Buy | $12 | $0.91 | +1,215.36% | 24 | Jun 25, 2025 | |
| ACLX Arcellx | Reiterates: Buy | $115 | $66.54 | +72.83% | 13 | Jun 16, 2025 | |
| ARTV Artiva Biotherapeutics | Assumes: Buy | $12 | $1.69 | +610.06% | 1 | Jun 11, 2025 | |
| AGEN Agenus | Upgrades: Buy | $25 | $4.86 | +414.40% | 18 | Jun 4, 2025 | |
| ANAB AnaptysBio | Upgrades: Buy | $22 → $38 | $24.26 | +56.64% | 10 | Jun 4, 2025 | |
| RAPT RAPT Therapeutics | Assumes: Buy | $48 | $8.05 | +496.27% | 1 | May 22, 2025 | |
| SABS SAB Biotherapeutics | Assumes: Buy | $10 | $2.58 | +287.60% | 1 | May 14, 2025 | |
| OLMA Olema Pharmaceuticals | Reiterates: Buy | $30 | $4.64 | +546.55% | 20 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 | $3.89 | +182.78% | 11 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $2.91 | +999.66% | 14 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $560 → $280 | $9.25 | +2,927.03% | 17 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $15.28 | +135.60% | 1 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $1.13 | +604.91% | 6 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $1.43 | +739.16% | 13 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $3.48 | +762.07% | 7 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $1.31 | +1,355.94% | 12 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $1.78 | +914.08% | 15 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $0.73 | +1,817.81% | 12 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $0.85 | +724.60% | 14 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.65 | +670.30% | 11 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $35 | $7.20 | +386.11% | 12 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.39 | - | 5 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $24 | $8.50 | +182.35% | 5 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $58 | $36.29 | +59.82% | 1 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $0.63 | +2,744.50% | 1 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $2.08 | - | 15 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $17.51 | +117.02% | 18 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $2.41 | +1,266.91% | 14 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $3.54 | - | 1 | Apr 25, 2024 | |
Jasper Therapeutics
Jul 7, 2025
Maintains: Buy
Price Target: $40 → $20
Current: $3.02
Upside: +562.25%
NextCure
Jul 1, 2025
Reiterates: Buy
Price Target: $3
Current: $0.46
Upside: +556.31%
Femasys
Jun 25, 2025
Reiterates: Buy
Price Target: $12
Current: $0.91
Upside: +1,215.36%
Arcellx
Jun 16, 2025
Reiterates: Buy
Price Target: $115
Current: $66.54
Upside: +72.83%
Artiva Biotherapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $12
Current: $1.69
Upside: +610.06%
Agenus
Jun 4, 2025
Upgrades: Buy
Price Target: $25
Current: $4.86
Upside: +414.40%
AnaptysBio
Jun 4, 2025
Upgrades: Buy
Price Target: $22 → $38
Current: $24.26
Upside: +56.64%
RAPT Therapeutics
May 22, 2025
Assumes: Buy
Price Target: $48
Current: $8.05
Upside: +496.27%
SAB Biotherapeutics
May 14, 2025
Assumes: Buy
Price Target: $10
Current: $2.58
Upside: +287.60%
Olema Pharmaceuticals
Apr 28, 2025
Reiterates: Buy
Price Target: $30
Current: $4.64
Upside: +546.55%
Apr 24, 2025
Reiterates: Buy
Price Target: $11
Current: $3.89
Upside: +182.78%
Apr 22, 2025
Reiterates: Buy
Price Target: $32
Current: $2.91
Upside: +999.66%
Apr 16, 2025
Maintains: Buy
Price Target: $560 → $280
Current: $9.25
Upside: +2,927.03%
Apr 9, 2025
Initiates: Buy
Price Target: $36
Current: $15.28
Upside: +135.60%
Apr 1, 2025
Reiterates: Buy
Price Target: $8
Current: $1.13
Upside: +604.91%
Apr 1, 2025
Reiterates: Buy
Price Target: $12
Current: $1.43
Upside: +739.16%
Mar 31, 2025
Reiterates: Buy
Price Target: $30
Current: $3.48
Upside: +762.07%
Mar 28, 2025
Reiterates: Buy
Price Target: $19
Current: $1.31
Upside: +1,355.94%
Mar 27, 2025
Reiterates: Buy
Price Target: $18
Current: $1.78
Upside: +914.08%
Mar 26, 2025
Reiterates: Buy
Price Target: $14
Current: $0.73
Upside: +1,817.81%
Mar 26, 2025
Reiterates: Buy
Price Target: $7
Current: $0.85
Upside: +724.60%
Mar 21, 2025
Reiterates: Buy
Price Target: $5
Current: $0.65
Upside: +670.30%
Mar 18, 2025
Reiterates: Buy
Price Target: $35
Current: $7.20
Upside: +386.11%
Mar 12, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.39
Upside: -
Feb 26, 2025
Upgrades: Buy
Price Target: $24
Current: $8.50
Upside: +182.35%
Feb 24, 2025
Reiterates: Buy
Price Target: $58
Current: $36.29
Upside: +59.82%
Feb 3, 2025
Reiterates: Buy
Price Target: $18
Current: $0.63
Upside: +2,744.50%
Jan 14, 2025
Reiterates: Neutral
Price Target: n/a
Current: $2.08
Upside: -
Jan 14, 2025
Reiterates: Buy
Price Target: $38
Current: $17.51
Upside: +117.02%
Nov 15, 2024
Reiterates: Buy
Price Target: $33
Current: $2.41
Upside: +1,266.91%
Apr 25, 2024
Reiterates: Neutral
Price Target: n/a
Current: $3.54
Upside: -